The share price of the cellular oncology drug developer, which counts Novartis, Johnson & Johnson and PureTech Health as investors, has doubled since it floated.

The Eli Lilly-backed liver disease drug developer floated at the top of its range to raise almost $128m, following $207m of venture funding.

Today's deal net contains news from Nexthink, Metalenz, Grapheal, CellulaRevolution and Astrata.

Eli Lilly and WuXi AppTec scored exits from the immunotherapy developer, which has seen its shares rocket 66% since it floated.

The Novo, Pfizer and Nan Fung-backed oncology therapy developer priced an upsized offering above its range and is now valued above $1bn.

Stanford spinout Bolt Biotherapeutics has raised more than twice as much as originally planned in an offering that also provided exits for corporates Pfizer, Novo and Fan Fung.

Immunocore has raised more than $258m in an upsized offering and an additional $15m in a concurrent private placement.

Merck & Co and UnitedHealth Group are set to exit the urologic cancer diagnostics technology provider in an acquisition by Veracyte.

The Cambrian Biopharma-backed cancer treatment developer floated above its range in an offering on the Nasdaq Global Market.

Gene-sequencing technology developer Vision Medicals has completed a $30.9m round led by Tencent that took its total funding to approximately $74m.